<DOC>
	<DOCNO>NCT01160770</DOCNO>
	<brief_summary>The objective study evaluate long-term safety effectiveness open-label clobazam treatment drop seizures subject LGS .</brief_summary>
	<brief_title>Safety Effectiveness Open-Label Clobazam Subjects With Lennox-Gastaut Syndrome</brief_title>
	<detailed_description>This multi-center , open-label study design evaluate long-term safety effectiveness clobazam adjunctive therapy subject LGS . Subjects enrol Lundbeck LLC ( formerly Ovation Pharmaceuticals , Inc. ) sponsor study 13108A/OV1002/NCT00162981 13110A/OV1012/NCT00518713 either complete study prematurely discontinue offer opportunity rollover open-label study . Subjects start common dose level 0.5 mg/kg , exceed 40 mg/day , must maintain dose level 48 hour . After 48 hour , investigator able increase , decrease maintain subject 's dose , maximum target daily dose 2.0 mg/kg ( maximum dose 80 mg/day ) . During treatment period , seizure record week precede study visit 30 day immediately follow study visit ( dependent Amendment approval ) . The subject subject 's caregiver record daily count seizure , include drop seizure subject 's seizure diary .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lennox Gastaut Syndrome</mesh_term>
	<mesh_term>Clobazam</mesh_term>
	<criteria>The subject subject 's legally authorize representative ( LAR ) must sign date institutional review board ( IRB ) /independent ethic committee ( IEC ) approve Informed Consent Form/Health Insurance Portability Accountability Act ( HIPAA ) Authorization ( require ) prior study participation . Previous participation Lundbecksponsored LGS study . Subject must weigh â‰¥12.5 kilogram . Male female subject must 2 60 year age time enrollment Phase 3 doubleblind study ( 13110A/OV1012/NCT00518713 ) 2 30 year age time enrollment Phase 2 doubleblind study ( 13108A/OV1002/NCT00162981 ) study . If female : Subject either childbearing potential , defined premenarchal , postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential , must comply method birth control acceptable investigator study , least 4 week prior study entry 4 week follow completion study . Subject breastfeeding . Subjects childbearing potential must negative serum pregnancy test Study Day 1 . In investigator 's opinion , parent caregiver must able keep accurate seizure diary . Greater 14 day elapse since subject receive his/her last dose study medication previous Lundbecksponsored LGS study . Subject serious severe adverse event previous Lundbecksponsored LGS study opinion investigator probably definitely related clobazam use precludes safe use clobazam . Subject anoxic episode require resuscitation within 6 month study entry . Subject history allergic reaction significant sensitivity benzodiazepine ingredient clobazam tablet . Subject take 3 concurrent antiepileptic drug ( AEDs ) . NOTE : Vagal Nerve Stimulator ( VNS ) ketogenic diet allow count three allow AEDs . Subject currently take longterm systemic steroid ( exclude inhale medication asthma treatment ) daily medication know exacerbate epilepsy . An exception make prophylactic medication , example , idiopathic nephrotic syndrome asthma . If subject take felbamate , take less 1 year prior study entry previous treatment felbamate result withdrawal due liver bone marrow adverse event . Subject experience idiosyncratic reaction AED , e.g. , carbamazepine result aplastic anemia agranulocytosis , topiramate result metabolic acidosis , felbamate result aplastic anemia hepatic failure , lamotrigine result skin irritation and/or rash . Subject show clinically significant history hypersensitivity central nervous system ( CNS ) active medication lead neurobehavioral aberration ( e.g. , increase biting , scratch , kick , hit ) . Subject take used investigational drug device 30 day prior screen , exception clobazam Lundbecksponsored study . Subject clinically significant unstable hepatic , hematological , renal , cardiovascular , gastrointestinal , pulmonary disease ongoing malignancy . Subject diagnosis sleep apnea . Subject compromise respiratory function severe respiratory insufficiency . Subject history severe muscle weakness , include myasthenia gravis . Subject clinically significant abnormal laboratory value electrocardiogram ( ECG ) abnormality . Subject progressive lesion confirm magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan . Subject history drug alcohol abuse . Subject history poor compliance past antiepileptic therapy . Subject inadequate supervision parent guardian . For reason , subject consider investigator unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Lennox-Gastaut Syndrome ( LGS )</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Drop Seizures</keyword>
	<keyword>Clobazam</keyword>
</DOC>